Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2017 IPOs In Review: US Biopharma Offerings Rise, Values Decline At Mid-Year

Executive Summary

Nineteen biopharma firms went public in the US during the first half of 2017, but as the number of IPOs increased, the average return on first-time offerings decreased, raising a key question: can this pace of first-time offerings continue in the second half?

Advertisement

Related Content

Commercial Capsules: Soriot, IPOs, Deals And Hemophilia Data
Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds
Biopharma IPOs Gain Momentum As Three More Launch In The US
After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three
Finance Watch: Two New VC Funds Raise $500m; One New US IPO; And Galena's 'Strategic Review'
IPO Update: Three Biopharma Offerings In January Contrast With Last Year’s Slow Start

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099134

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel